CLCN2

Across TCGA pan-cancer cohorts, CLCN2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CLCN2 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CLCN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLCN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, LUAD, and GBM are the cancer types where CLCN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.148	0.904	<.001	30	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	24	view →
GBM	OS	Median	All	0.020	0.416	<.001	12	view →
UCEC	DFS	Median	All	0.968	0.619	.013	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.166	0.555	.038	6	view →
LUSC	DFS	Median	II,III,IV	0.347	0.714	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CLCN2–KIRP (OS)

Open the KIRP breakdown →